Business
-
German biotech startup AATec Medical announced that it has raised €4 million prior to a series A financing, with the funds going to development of the company’s ATL-105 inhaled recombinant alpha-1 antitrypsin (AAT) for the… Read more . . .
-
Inhaled vaccine developer Ethris and CDMO Lonza have announced that Lonza will develop spray-dried formulations of Ethris mRNA-based vaccine candidates. Earlier this year, Ethris announced that it would receive $5 million from the Coalition for… Read more . . .
-
Chiesi Group announced that it will spend €430 million to construct a new manufacturing facility on a site that it has acquired in Nerviano, Italy. The site will produce metered dose inhalers with low global warming… Read more . . .
-
US-based Paratek Pharmaceuticals will acquire all outstanding shares of intranasal drug developer Optinose in a deal worth up to $330 million, the companies said. According to the announcement, both companies’ boards have approved the deal,… Read more . . .
-
Cyrano Therapeutics has acquired an exclusive license to use Resyca’s soft mist nasal spray technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral hyposmia. According to the announcement, the Phase 2 FLAVOR… Read more . . .
-
DPI developer Chance Pharmaceuticals announced the completion of a financing round with participation from Heda Health Fund and Qihang Venture Capital, with proceeds intended to support Phase 3 trials of CXG87 inhaled dry powder budesonide… Read more . . .
-
Israeli biotech Polyrizon announced that it is beginning preclinical development of an intranasal naloxone formulation based on the company’s Trap and Target mucoadhesive technology. The company said that Fabio Sonvico of the University of Parma,… Read more . . .
-
Armata Pharmaceuticals announced details of an additional secured credit agreement with Innoviva Strategic Opportunities, the company’s largest shareholder. Armata said that it will pay interest at a 14% annual rate on the $10 million loan… Read more . . .
-
Emergent BioSolutions and Swiss biotech Rocketvax have announced that Emergent will make a strategic investment in Rocketvax parent company Swiss Rockets and will take over manufacturing and commercialization activities for 4 of Rocketvax’s intranasal vaccine candidates.… Read more . . .
-
Altamira Therapeutics said that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent covering the formulation of Bentrio bentonite-based nasal spray. Bentrio received 510(k) clearance in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden